Show simple item record

A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose

dc.contributor.authorTsuda, Y
dc.contributor.authorParkins, CJ
dc.contributor.authorCaposio, P
dc.contributor.authorFeldmann, F
dc.contributor.authorBotto, S
dc.contributor.authorBall, S
dc.contributor.authorMessaoudi, I
dc.contributor.authorCicin-Sain, L
dc.contributor.authorFeldmann, H
dc.contributor.authorJarvis, MA
dc.date.accessioned2017-03-17T13:24:49Z
dc.date.issued2015-03-25
dc.description.abstractEbola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.en_GB
dc.description.sponsorshipWe thank Dr U. Koszinowski (Max von Pettenkofer-Institute, Ludwig-Maximilians-University, Germany) for providing the pSMfr3 MCMV BAC, and Dr D. Court (NCI-Frederick, MD) for providing the lambda-based recombination system used to construct the original MCMV/ZEBOV-NPCTL construct. We appreciate K. Marshall (VGTI, OR) and J. Bailey (NIAID, MT) for their organization and coordination of animals used in the study. We also thank the members of Rocky Mountain Veterinary Branch (DIR, NIAID, NIH) for assistance with animal care. Finally, we thank Drs H. Ebihara (DIR, NIAID, NIH), A. Marzi (DIR, NIAID, NIH), P. Barry (University of California at Davis, CA), M. Cranfield (Mountain Gorilla Veterinary Project, Baltimore, MD) for insightful discussions. This study was supported by R21 (AI088442) and the Intramural Research Program of the NIAID, NIH; and University of Plymouth, School of Biomedical and Healthcare Sciences internal funding.en_GB
dc.identifier.citation, Vol. 33, pp. 2261 - 2266en_GB
dc.identifier.doi10.1016/j.vaccine.2015.03.029
dc.identifier.urihttp://hdl.handle.net/10871/26664
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/25820063en_GB
dc.subjectCytomegalovirusen_GB
dc.subjectDisseminatingen_GB
dc.subjectDurableen_GB
dc.subjectEbolaen_GB
dc.subjectEbolavirusen_GB
dc.subjectGreat apesen_GB
dc.subjectMouseen_GB
dc.subjectProtectionen_GB
dc.subjectVaccineen_GB
dc.subjectAnimalsen_GB
dc.subjectBody Weighten_GB
dc.subjectCytomegalovirusen_GB
dc.subjectDisease Models, Animalen_GB
dc.subjectEbolavirusen_GB
dc.subjectFemaleen_GB
dc.subjectGenetic Vectorsen_GB
dc.subjectHemorrhagic Fever, Ebolaen_GB
dc.subjectMice, Inbred C57BLen_GB
dc.subjectSurvival Analysisen_GB
dc.subjectVaccinationen_GB
dc.subjectViral Vaccinesen_GB
dc.titleA cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single doseen_GB
dc.typeArticleen_GB
dc.date.available2017-03-17T13:24:49Z
exeter.place-of-publicationNetherlandsen_GB
dc.descriptionThis is the author accepted manuscript. The final version is available fromElsevier via the DOI in this record.en_GB
dc.identifier.journalVaccineen_GB


Files in this item

Name:
Revised Version (Tracked and ...
Size:
279.8Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record